NNVC NANOVIRICIDES, INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1379006 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.9%
TTM EPS YoY-8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-179.2%
ROA-135.9%
ROIC (approx.)-196.2%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets33.5%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | — |
| R&D expense | $4.71M | $5.55M | $5.44M | $6.39M | $5.78M |
| SG&A expense | $3.60M | $4.04M | $3.08M | $2.55M | $2.33M |
| Operating income | -$8.31M | -$9.59M | -$8.52M | -$8.94M | -$8.11M |
| Interest expense | — | $149 | $49,808 | $938 | $5,123 |
| Pretax income | -$8.22M | — | — | — | -$8.11M |
| Net income | -$8.22M | -$9.47M | -$8.29M | -$8.59M | -$8.11M |
| EBITDA | -$7.79M | -$8.86M | -$7.77M | -$8.20M | -$7.40M |
| EPS (basic) | -0.41 | -0.63 | -0.70 | -0.74 | -0.70 |
| EPS (diluted) | -0.41 | -0.63 | -0.70 | -0.74 | -0.70 |
| Weighted avg. shares (diluted) | 20.19M | 15.12M | 11.87M | 11.63M | 11.53M |
| Balance sheet | |||||
| Cash & equivalents | $2.79M | $1.56M | $4.80M | $8.15M | $14.07M |
| Current assets | $3.16M | $1.67M | $4.97M | $8.45M | $14.42M |
| PP&E, net | $6.40M | $6.83M | $7.51M | $8.11M | $8.69M |
| Intangibles | $308,769 | $317,039 | $325,308 | $333,578 | $341,848 |
| Total assets | $9.87M | $8.82M | $12.82M | $16.90M | $23.49M |
| Current liabilities | $1.19M | $1.31M | $1.36M | $534,250 | $412,837 |
| Total liabilities | $1.20M | $1.30M | $1.36M | $2.03M | $412,837 |
| Shareholders' equity | $8.68M | $7.52M | $11.46M | $14.87M | $23.08M |
| Shares outstanding | 23.01M | 16.61M | 13.14M | 11.70M | 11.59M |
| Cash flow statement | |||||
| Operating cash flow | -$7.70M | -$8.48M | -$6.32M | -$5.67M | -$5.89M |
| Capital expenditure | $84,317 | $56,964 | $156,560 | $151,712 | $324,348 |
| Free cash flow | -$7.78M | -$8.54M | -$6.47M | -$5.82M | -$6.22M |
| Investing cash flow | -$84,317 | -$56,964 | -$156,560 | -$151,712 | -$324,348 |
| Financing cash flow | $9.02M | $5.30M | $3.12M | -$94,788 | -$234,716 |
| Depreciation & amortization | $517,016 | $735,536 | $750,744 | $739,259 | $715,055 |
| Stock-based compensation | — | — | $563 | $44,000 | — |
Free plan shows the latest 5 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.